纳米抗体示踪剂用于实体瘤EpCAM的免疫PET显像:一项临床前研究
该临床前研究构建了靶向上皮细胞黏附分子(EpCAM)的68Ga/18F标记纳米抗体免疫PET探针,在人结直肠癌LS174T和食管癌OE19细胞衍生肿瘤模型中评估药代动力学与诊断准确性,[18F]AIF-RESCA-EPCD6背景低、靶向特异性好,作者认为其免疫PET显像可能有助于更好地使用EpCAM靶向治疗。
要点
- 构建了6种靶向EpCAM的单域抗体(EPCD1-6),并分别用68Ga和18F标记。
- [68Ga]Ga-NOTA-EPCD3在LS174T模型中平均肿瘤摄取为2.06 ± 0.124%ID/g(n = 3)。
- [18F]AIF-RESCA-EPCD6在OE19模型中平均肿瘤摄取为4.70 ± 0.26%ID/g(n = 3),阻断组为0.17 ± 0.25%ID/g(n = 3),P < 0.001。
核心结论
- 作者开发了一系列靶向人EpCAM的68Ga/18F标记纳米抗体示踪剂,[18F]AIF-RESCA-EPCD6免疫PET显像可能通过无创展示靶点表达动态,有助于更好地使用EpCAM靶向治疗。
研究设计与样本
- 临床前研究:通过工程化改造6种靶向EpCAM的单域抗体(EPCD1-6),用68Ga(T1/2 = 1.1 h)和18F(T1/2 = 110 min)标记,在LS174T结直肠癌和OE19食管癌细胞衍生肿瘤模型中研究药代动力学和诊断准确性。
主要发现
- 基于前三种示踪剂([68Ga]Ga-NOTA-EPCD1、[68Ga]Ga-NOTA-EPCD2和[68Ga]Ga-NOTA-EPCD3)的体外结合亲和力和体内药代动力学,选择[68Ga]Ga-NOTA-EPCD3用于肿瘤显像,在LS174T细胞衍生肿瘤模型中平均肿瘤摄取为2.06 ± 0.124%ID/g(n = 3)。
- [18F]AIF-RESCA-EPCD3在同一肿瘤模型中显示可比较的肿瘤摄取,为1.73 ± 0.0471%ID/g(n = 3)。
- [68Ga]Ga-NOTA-EPCD3在OE19细胞衍生肿瘤模型中进一步验证,平均肿瘤摄取为4.27 ± 1.16%ID/g,肝脏摄取为13.5 ± 1.30%ID/g(n = 3)。
- Cy7-EPCD3近红外荧光显像证实了体内药代动力学和相对较高的肝脏蓄积。
- 另外合成了三种18F标记纳米抗体示踪剂([18F]AIF-RESCA-EPCD4、[18F]AIF-RESCA-EPCD5和[18F]AIF-RESCA-EPCD6),发现[18F]AIF-RESCA-EPCD6药代动力学最佳、背景低,在皮下接种OE19肿瘤模型中平均摄取为4.70 ± 0.26%ID/g(n = 3),而EPCD6阻断组相应肿瘤摄取为0.17 ± 0.25%ID/g(n = 3),显著更低(P < 0.001),表明示踪剂靶向特异性。
关键数值与推荐
- [68Ga]Ga-NOTA-EPCD3在LS174T细胞衍生肿瘤模型中平均肿瘤摄取为2.06 ± 0.124%ID/g(n = 3)。
- [18F]AIF-RESCA-EPCD3在LS174T细胞衍生肿瘤模型中平均肿瘤摄取为1.73 ± 0.0471%ID/g(n = 3)。
- [68Ga]Ga-NOTA-EPCD3在OE19细胞衍生肿瘤模型中平均肿瘤摄取为4.27 ± 1.16%ID/g、肝脏摄取为13.5 ± 1.30%ID/g(n = 3)。
- [18F]AIF-RESCA-EPCD6在皮下接种OE19肿瘤模型中平均肿瘤摄取为4.70 ± 0.26%ID/g(n = 3),EPCD6阻断组为0.17 ± 0.25%ID/g(n = 3),P < 0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Epithelial cell adhesion molecule (EpCAM) is a potential therapeutic target and anchoring molecule for circulating and disseminated tumour cells (CTC/DTC) in liquid biopsy. In this study, we aimed to construct EpCAM-specific immuno-positron emission tomography (immunoPET) imaging probes and assess the diagnostic abilities in preclinical cancer models. METHODS: By engineering six single-domain antibodies (e.g., EPCD1 - 6) targeting EpCAM of different binding properties and labelling with 68Ga (T1/2 = 1.1 h) and 18F (T1/2 = 110 min), we developed a series of EpCAM-targeted immunoPET imaging probes. The probes' pharmacokinetics and diagnostic accuracies were investigated in cell-derived human colorectal (LS174T) and esophageal cancer (OE19) tumour models. RESULTS: Based on in vitro binding affinities and in vivo pharmacokinetics of the first three tracers ([68Ga]Ga-NOTA-EPCD1, [68Ga]Ga-NOTA-EPCD2, and [68Ga]Ga-NOTA-EPCD3), we selected [68Ga]Ga-NOTA-EPCD3 for tumour imaging which showed an average tumour uptake of 2.06 ± 0.124%ID/g (n = 3) in LS174T cell-derived tumour model. Development and characterisation of [18F]AIF-RESCA-EPCD3 showed comparable tumour uptake of 1.73 ± 0.0471%ID/g (n = 3) in the same tumour model. Further validation of [68Ga]Ga-NOTA-EPCD3 in OE19 cell-derived tumour model showed an average tumour uptake of 4.27 ± 1.16%ID/g and liver uptake of 13.5 ± 1.30%ID/g (n = 3). Near-infrared fluorescence imaging with Cy7-EPCD3 confirmed the in vivo pharmacokinetics and relatively high liver accumulation. We further synthesized another three 18F-labeled nanobody tracers ([18F]AIF-RESCA-EPCD4, [18F]AIF-RESCA-EPCD5, and [18F]AIF-RESCA-EPCD6) and found that [18F]AIF-RESCA-EPCD6 had the best pharmacokinetics with low background. [18F]AIF-RESCA-EPCD6 showed explicit uptake in the subcutaneously inoculated OE19 tumour model with an average uptake of 4.70 ± 0.26%ID/g (n = 3). In comparison, the corresponding tumour uptake (0.17 ± 0.25%ID/g, n = 3) in the EPCD6 blocking group was substantially lower (P < 0.001), indicating the targeting specificity of the tracer. CONCLUSIONS: We developed a series of 68Ga/18F-labeled nanobody tracers targeting human EpCAM. ImmunoPET imaging with [18F]AIF-RESCA-EPCD6 may facilitate better use of EpCAM-targeted therapeutics by noninvasively displaying the target's expression dynamics.
引用
- Xu D, Zhang Y, Huang W, et al. ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study. Eur J Nucl Med Mol Imaging. 2024. PMID: 39249490. doi:10.1007/s00259-024-06910-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。